Johnson & Johnson ROA 2006-2018 | JNJ

Current and historical return on assets (ROA) values for Johnson & Johnson (JNJ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Johnson & Johnson ROA for the three months ending September 30, 2018 was 13.90%.
Johnson & Johnson ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $1.54B $155.70B 0.99%
2018-06-30 $1.37B $155.37B 0.88%
2018-03-31 $1.25B $156.63B 0.80%
2017-12-31 $1.30B $157.30B 0.85%
2017-09-30 $15.83B $155.66B 10.65%
2017-06-30 $16.34B $152.81B 11.28%
2017-03-31 $16.51B $144.92B 11.66%
2016-12-31 $16.54B $141.21B 11.86%
2016-09-30 $15.94B $140.37B 11.60%
2016-06-30 $15.03B $139.81B 11.08%
2016-03-31 $15.55B $136.23B 11.62%
2015-12-31 $15.41B $133.41B 11.69%
2015-09-30 $14.72B $133.27B 11.23%
2015-06-30 $16.11B $132.04B 12.32%
2015-03-31 $15.92B $128.59B 12.10%
2014-12-31 $16.32B $130.36B 12.30%
2014-09-30 $17.32B $132.10B 12.99%
2014-06-30 $15.55B $135.20B 11.78%
2014-03-31 $15.06B $133.33B 11.65%
2013-12-31 $13.83B $132.68B 10.94%
2013-09-30 $12.88B $126.93B 10.43%
2013-06-30 $12.87B $124.33B 10.59%
2013-03-31 $10.44B $121.54B 8.74%
2012-12-31 $10.85B $121.35B 9.19%
2012-09-30 $8.50B $118.95B 7.32%
2012-06-30 $8.74B $115.75B 7.64%
2012-03-31 $10.11B $116.19B 8.91%
2011-12-31 $9.67B $113.64B 8.68%
2011-09-30 $11.40B $111.82B 10.48%
2011-06-30 $11.61B $112.11B 11.02%
2011-03-31 $12.28B $108.15B 12.23%
2010-12-31 $13.33B $102.91B 13.79%
2010-09-30 $13.60B $98.25B 14.36%
2010-06-30 $13.53B $92.30B 14.54%
2010-03-31 $13.29B $93.44B 14.47%
2009-12-31 $12.27B $94.68B 13.64%
2009-09-30 $12.77B $91.56B 14.60%
2009-06-30 $12.74B $87.44B 14.72%
2009-03-31 $12.86B $86.10B 14.83%
2008-12-31 $12.95B $84.91B 14.94%
2008-09-30 $12.61B $87.72B 14.71%
2008-06-30 $11.85B $88.11B 14.20%
2008-03-31 $11.60B $86.00B 14.49%
2007-12-31 $10.58B $80.95B 13.76%
2007-09-30 $10.37B $78.67B 13.97%
2007-06-30 $10.58B $74.68B 15.14%
2007-03-31 $10.32B $73.07B 15.53%
2006-12-31 $11.05B $70.56B 17.34%
2006-09-30 $10.98B $61.24B 18.06%
2006-06-30 $10.76B $60.99B 18.04%
2006-03-31 $10.53B $62.13B 18.14%
2005-12-31 $10.06B $58.86B 17.93%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $390.684B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $262.581B 14.80
Novartis AG (NVS) Switzerland $204.469B 17.47
Merck (MRK) United States $201.378B 17.45
AbbVie (ABBV) United States $134.913B 11.98
Eli Lilly (LLY) United States $119.915B 21.08
Sanofi (SNY) France $111.886B 13.85
Novo Nordisk (NVO) Denmark $108.835B 17.67
AstraZeneca (AZN) United Kingdom $103.621B 12.86
GlaxoSmithKline (GSK) United Kingdom $101.752B 13.68
Bristol-Myers Squibb (BMY) United States $86.262B 14.21